Evaluating Stem Cell Fortified Eye Drops for Improving Tear Film and Dry Eye Symptoms in Adults with Dry Eye Disease and Cataract

What this Trial Is About

Dry Eye Disease DED is a condition affecting the surface of the eye, causing discomfort, unstable tear film, and possible vision problems. Cataract, a clouding of the eyes lens, is the leading cause of preventable blindness worldwide, affecting millions and linked to aging and factors like UV exposure and diabetes. This research evaluates stem cell-fortified eye drops as a potential new treatment to improve tear film stability, tear volume, and symptoms in people with DED, using advanced diagnostic tools. Participants in this study will receive eye drops containing mesenchymal stem cells. The treatment involves applying two drops three times daily for 12 weeks to cases with corneal opacity. The study focuses on assessing changes in eye structure clarity and visual function over this period. The study is interventional, with no masking or blinding, and targets adults aged 18 to 80 years. During the study, participants will be monitored through slit-lamp grading and anterior segment optical coherence tomography AS-OCT at 12 weeks to measure structural clarity. Visual acuity will also be evaluated to assess functional improvement. The research aims to understand the potential benefits of these eye drops on eye health and symptoms, with safety and symptom changes tracked throughout the treatment period.

Assessment of CataClear, Tear Film Stability, Tear Volume, and Dry Eye Symptoms Using Stem Cells Fortified Eye Drops